(Q41753179)

8 October 2017

title

RSV infection among children born moderately preterm in a community-based cohort (English)

1 reference

8 October 2017

3

Sijmen A Reijneveld

1 reference

8 October 2017

Rolof G P Gijtenbeek

1

1 reference

8 October 2017

Jorien M Kerstjens

2

1 reference

8 October 2017

Eric J Duiverman

4

1 reference

8 October 2017

Arend F Bos

5

1 reference

8 October 2017

Elianne J L E Vrijlandt

6

1 reference

8 October 2017

publication date

6 September 2014

1 reference

European Journal of Pediatrics

8 October 2017

published in

1 reference

8 October 2017

volume

174

1 reference

8 October 2017

issue

4

1 reference

8 October 2017

page(s)

435-442

1 reference

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Joint policy statement--guidelines for care of children in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Immunoglobulin profile of the preterm baby

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

A comparison of four scoring methods based on the parent-rated Strengths and Difficulties Questionnaire as used in the Dutch preventive child health care system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Support for the global feasibility of the Ages and Stages Questionnaire as developmental screener.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Developmental delay in moderately preterm-born children at school entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33 weeks GA or more: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Variation of respiratory syncytial virus and the relation with meteorological factors in different winter seasons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Are late preterm infants as susceptible to RSV infection as full term infants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Respiratory syncytial virus (RSV) in infants hospitalized for acute lower respiratory tract disease: incidence and associated risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Epidemiologic, socioeconomic, and clinical factors associated with severity of respiratory syncytial virus infection in previously healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Moderately preterm children have more respiratory problems during their first 5 years of life than children born full term.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Respiratory syncytial virus infection: therapy and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-014-2415-2

Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany

21 January 2018

1 reference

12 December 2020

Respiratory syncytial virus bronchiolitis: prevention and treatment

1 reference

12 December 2020

Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy

1 reference

12 December 2020

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Systematic review of the biology and medical management of respiratory syncytial virus infection

1 reference

12 December 2020

Current concepts of the pathogenesis of RSV bronchiolitis

1 reference

12 December 2020

Chest physiotherapy using passive expiratory techniques does not reduce bronchiolitis severity: a randomised controlled trial

1 reference

12 December 2020

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

12 December 2020

Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.

1 reference

12 December 2020

10.1007/S00431-014-2415-2

Identifiers

DOI

1 reference

8 October 2017

1 reference